Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Acumen Pharmaceuticals Inc., 3 years.
Acumen Pharmaceuticals Inc.
Director
Taysha Gene Therapies Inc.
Director
Verrica Pharmaceuticals Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 3, 2026 | Acumen Pharmaceuticals Inc. | Grant or award | +35,500 | — | — |
| Jun 1, 2026 | Taysha Gene Therapies Inc. | Grant or award | +21,335 | — | — |
| Jun 4, 2025 | Acumen Pharmaceuticals Inc. | Grant or award | +12,800 | — | — |
| Jun 2, 2025 | Taysha Gene Therapies Inc. | Grant or award | +56,623 | — | — |
| Nov 26, 2024 | Verrica Pharmaceuticals Inc. | Gift | +50,000 | — | — |
| Nov 22, 2024 | Verrica Pharmaceuticals Inc. | Open-market purchase | +1,123,595 | — | — |
| May 29, 2024 | Taysha Gene Therapies Inc. | Grant or award | +49,220 | — | — |
| Aug 16, 2023 | Taysha Gene Therapies Inc. | Open-market purchase | +388,889 | $0.90 | $350,000 |
| Aug 16, 2023 | Taysha Gene Therapies Inc. | Open-market purchase | +388,889 | $0.90 | $350,000 |
| Aug 16, 2023 | Taysha Gene Therapies Inc. | Gift | +50,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.